Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Inquiry

General health and science information has long served as a foundational resource for public understanding of medical conditions and treatment options. In this context, discussions around medications like Fosamax have historically focused on their primary indications, such as osteoporosis management, and general safety profiles. The legacy of such information emphasizes broad awareness of drug benefits and potential side effects, often framed within a clinical or patient-education setting. As this knowledge base evolves, attention has increasingly turned to specific adverse outcomes that may arise from prolonged pharmaceutical exposure. One area of particular interest involves the relationship between bisphosphonate use and rare but serious conditions affecting the oral cavity. This shift in focus moves from general health literacy toward a more targeted examination of occupational and environmental risk factors. In occupational settings, where individuals may have sustained contact with pharmaceutical agents or their residues, the question of causation becomes more pressing. The transition from a general health context to a specific exposure concern requires careful consideration of how routine medication use, in certain populations or work environments, might correlate with elevated risk for conditions such as osteonecrosis of the jaw. This pivot underscores the need for nuanced inquiry into exposure pathways without presuming mechanistic links.

Understanding Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ often involves pain, swelling, infection, and exposed bone in the mandible or maxilla, and diagnosis is typically based on clinical examination and imaging. The question of whether Fosamax causes ONJ is addressed in the drug's prescribing information. The label explicitly states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This association is supported by mechanistic pathways that involve bisphosphonate-induced suppression of bone turnover. Bisphosphonates like Fosamax inhibit osteoclast activity, which reduces bone resorption and can lead to decreased bone remodeling. In the jawbone, which has high turnover rates and is subject to frequent microtrauma from chewing, this suppression may impair the ability to repair minor injuries, particularly after invasive dental procedures. The multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique biology of the jawbone that may predispose it to ONJ under bisphosphonate therapy.

Risk Factors and Clinical Evidence

Risk factors for developing ONJ while taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between exposure to Fosamax and documented harm from ONJ is variable. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a known adverse event, its incidence in clinical trials was low and not statistically different from placebo, indicating that other factors, such as underlying risk factors, may play a significant role.

Adequacy of Warnings and Causation Considerations

Regarding the adequacy of warnings, the Fosamax label includes a specific section on Osteonecrosis of the Jaw under Warnings and Precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section describes the condition, associated risk factors, and recommendations for management, including discontinuation of bisphosphonate treatment before invasive dental procedures. The label also notes that the optimal duration of use has not been determined, and for patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This warning provides clinicians with guidance to mitigate risk. For affected patients, causation-related considerations involve assessing individual risk factors, duration of Fosamax use, and the temporal relationship between drug exposure and ONJ onset. The presence of known risk factors, such as recent dental procedures or concomitant medications, may strengthen the association. However, the low incidence in clinical trials and the similarity to placebo rates suggest that ONJ is not a common adverse effect and may require a combination of predisposing factors to manifest. In summary, Fosamax is associated with ONJ, as documented in its prescribing information and supported by mechanistic understanding of bisphosphonate effects on bone turnover. The risk is influenced by duration of use, dental procedures, and other patient-specific factors. Warnings in the label are adequate to inform clinicians and patients, but individual risk assessment remains important for prevention and management.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the association between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that has been associated with osteonecrosis of the jaw (ONJ) in its prescribing information. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The mechanism involves suppression of bone turnover, particularly in the jawbone, which may impair healing after dental procedures.

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease. Duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How common is ONJ in Fosamax clinical trials?

In placebo-controlled clinical studies, the percentages of patients with ONJ symptoms were similar in the Fosamax and placebo groups, indicating a low incidence that was not statistically different from placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that ONJ is rare and may require additional risk factors.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.